# Clinical Trial of Efficacy and Safety of Levopront® 30 mg/5 ml in Patients With Dry Cough

> **NCT03837938** · PHASE3 · COMPLETED · sponsor: **Dompé Farmaceutici S.p.A** · enrollment: 184 (actual)

## Conditions studied

- Cough

## Interventions

- **DRUG:** Levopront® syrup 30 mg/5 ml
- **DRUG:** Libexin®

## Key facts

- **NCT ID:** NCT03837938
- **Lead sponsor:** Dompé Farmaceutici S.p.A
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-09
- **Primary completion:** 2018-03-06
- **Final completion:** 2018-07-31
- **Target enrollment:** 184 (ACTUAL)
- **Last updated:** 2024-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03837938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03837938, "Clinical Trial of Efficacy and Safety of Levopront® 30 mg/5 ml in Patients With Dry Cough". Retrieved via AI Analytics 2026-08-25 from https://api.ai-analytics.org/clinical/NCT03837938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*